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Despite improvements that occurred in the last decades in the acute myeloid leukemia (AML) treatment, clinical results are still
unsatisfactory. More eﬀective therapies are required, and innovative approaches are ongoing, including the discovery of novel
antileukemia natural compounds. Several studies have described the activity of extracts from mushrooms which produce
compounds that exhibited immunological and antitumor activities. The latter has been demonstrated to be promoted in vitro by
mushroom polysaccharides via induction of apoptosis. However, the antileukemia activity of these compounds on primary cells
is still not reported. In the present study, we examined the in vitro eﬀects of Tramesan (TR), a bioactive compound extracted
from Trametes versicolor, on leukemic cell lines and primary cells. Our results demonstrated that TR induced a marked growth
inhibition of leukemic cell lines and primary cells from AML patients. The antiproliferative eﬀects of TR were associated in
primary AML cells with a signiﬁcant increase of apoptosis. No signiﬁcant cytotoxic eﬀects were observed in normal peripheral
blood mononuclear cells (MNC) from healthy donors. Our data demonstrated a cytotoxic activity of TR on leukemia cells
prompting further translational applications. Ongoing studies are elucidating the molecular mechanisms underlying its
antileukemic activity.
1. Introduction
Acute leukemia is a disorder of the hematopoietic system
characterized by clonal proliferation of variably diﬀerentiated
myeloid or lymphoid precursors [1]. These hematological
disorders show a high level of genetic complexity, which is
the major explanation of the high rate of chemotherapy
failure and of the result stagnation over the last decades [1].
Therefore, eﬀorts have been made to identify novel therapeu-
tic approaches aimed at overcoming drug resistance and
exploring novel approaches based on chemo-free strategies.
The successful example of the acute promyelocytic leukemia,
nowadays treated in the majority of the cases without chemo-
therapy by regimen based on the combined use of retinoic
acid and arsenic trioxide [2], is worth mentioning. On this
basis, many attempts are ongoing to identify other similar
approaches. In fact, besides targeted therapies active on
leukemia-speciﬁc aberrant molecular alterations [3], an
increasing number of studies are directed toward the drug
discovery attempt, including the evaluation of natural
compounds on diﬀerent pathologies [4–6].
Mushrooms are rich sources of natural compounds
used as biological response modiﬁers for a long time in
oriental medicine and nowadays also in Western countries
[7–9]. Mushrooms have emerged as a rich font of antioxi-
dant, immunomodulating, anti-inﬂammatory, antimicrobial,
and anticancer [10] compounds. Among diﬀerent extracts
from mushrooms, polysaccharides are important bioactive
molecules and known as potent inhibitors of proliferation
and apoptosis inducers in in vitro experimental models. In
particular, the antitumor activity of PSK, a protein-bound
polysaccharide obtained from the fungus Trametes versicolor
(T. versicolor), has been documented in in vitro and
in vivo experimental models [11]. Eﬃcacy of the adjuvant
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immunotherapy with PSK was also demonstrated in
human clinical trials [12–14]. Moreover, the combination
of PSK with chemotherapy or radiotherapy has been
shown to increase the eﬃcacy of the latter in solid cancer
treatments [7].
To date, few studies have reported the antineoplastic
activity of PSK in hematologic models [11, 15–17]. In
leukemia cell line, it was demonstrated that PSK exerted an
antiproliferative and proapoptotic activity in HL-60 myeloid
cell line, via activation of the mitochondrial and the p38
MAPK signaling cascades [16, 17].
Previous studies from our group have demonstrated that
nonpuriﬁed extracts from the ﬁltrates of L. edodes and T.
versicolor inhibited mycotoxin synthesis in diﬀerent fungi
[18–20]. The mechanism of inhibition seems related to the
promotion of fungal antioxidant activity on counteracting
redox unbalance. It is now established that mycotoxigenic
fungi are able to vehiculate the unscavenged ROS toward
toxin synthesis.
Our group has patented a polysaccharidic fraction,
Tramesan (TR), isolated from the liquid culture of the edible
basidiomycete T. versicolor (Patent number RM2012A000573),
able to signiﬁcantly inhibit the synthesis of carcinogenic
mycotoxins produced from diﬀerent fungi (such as Aspergillus
ﬂavus, A. parasiticus, and Fusarium), by promoting an
antioxidant activity [18, 20, 21].
The aim of this study was to investigate the activity of TR
on leukemia cells by assessing proliferation inhibition and
apoptosis induction on leukemia cell lines and on primary
acute myeloid leukemia (AML) cells.
2. Materials and Methods
2.1. Fungal Strain and Growth Culture Conditions. The
basidiomycete Trametes versicolor CF 117 was supplied from
the mushroom collection of the laboratory of Mycology and
Plant Pathology directed from Professor Corrado Fanelli
(Sapienza University of Rome). The isolates were kept in
potato dextrose agar (PDA) medium at 4°C, and the cultures
have been renewed every 30 days.
2.2. Fungal Growth Substrate. T. versicolor was grown for
7 days in potato dextrose broth (PDB) and incubated
at 25°C. The liquid culture was homogenized, in sterile con-
dition in a Waring blender 8012. After homogenization, 5%
(v/v) of the fungal culture was subsequently inoculated in
500mL of PDB in 1L Erlenmeyer ﬂask and the T. versicolor
cultures were incubated for 14 days at 25°C under shaken
conditions (100 rpm). The mycelia were then separated from
the culture ﬁltrates by subsequent ﬁltrations with diﬀerent
size ﬁlters (Whatman) to eliminate all the mycelia. The
obtained culture ﬁltrate was lyophilized and utilized for
subsequent analyses.
2.3. Exopolysaccharide Extraction and Puriﬁcation. The
lyophilized T. versicolor culture ﬁltrate (1 g) was dissolved
in 30mL of ultrapure H2O and ﬁltrated to separate the
insoluble from the soluble part. The sample was then
incubated at 4°C for 2 h, and at the same time, a solution of
absolute ethanol was cooled at 4°C. The cooled culture ﬁltrate
was added slowly to cooled ethanol, mixing with a glass rod.
The precipitate was recovered by centrifugation at 4000 rpm
for 20min at 4°C. The recovered pellet was resuspended in
4mL of ultrapure H2O and 4mL of 20mM phosphate buﬀer
pH7.5 to achieve the optimal conditions of ionic strength
and pH for pronase E (Sigma-Aldrich) activity. The pro-
teolysis was carried out at 37°C overnight. The elimination of
salts and amino acids was performed through dialysis versus
H2O, utilizing membrane of 12000Da cutoﬀ. The dialyzed
samples were lyophilized and subjected to total carbohydrate
determination by Yemm and Willis [22].
To separate, on the basis of their molecular weight, the
exopolysaccharides precipitated with EtOH and present in
T. versicolor culture ﬁltrates, a size exclusion chromatogra-
phy was performed. The mobile phase was NaNO3 0.05M
degassed for about 30min and ﬁltered twice with Millipore
0.45μm ﬁlters. The Sephacryl S-300 (1.6 id× 90 cm) column
was equilibrated with the eluent for about 30 h, with a ﬂux of
about 6mL/h. The gel performances of the column allow
to discriminate polysaccharides with a molecular weight
between 2 and 400 kDa. About 40mg of the sample was
dissolved in 1.9mL of 50mM NaNO3, the solution was
centrifuged for 10min at 13000 rpm, and subsequently it
was loaded in a column. The column was connected to a
refractive index detector. Each fraction was collected every
20min during 30 h.
The chromatographic fraction containing only poly-
saccharides (TR) was used for biological activity assays.
The polysaccharide TR, isolated and puriﬁed was
patented from our group (Patent number RM2012A00057).
2.4. Cell Lines and Primary Samples. Human myeloid (OCI-
AML3) and lymphoid (Jurkat) cell lines were maintained
in RPMI 1640 medium containing 10% heat-inactivated
fetal calf serum (FCS), 1mM L-glutamine, and 50μg/mL
penicillin/streptomycin (Gibco, Milan), in a humidiﬁed
atmosphere containing 5% CO2 at 37
°C. Cell lines were
harvested in log-phase growth for all experiments, washed,
and cultured to the appropriate concentration in RPMI
10% FCS±TR at scalar concentrations (0.5–2mg/mL).
Peripheral blood (PB) samples and bone marrow (BM)
aspirate samples were obtained from normal donors and
from 4 AML patients, respectively, all referred to our
Hematology at Sapienza University of Rome, Italy. Written
informed consent for in vitro studies was obtained from
donors and patients in accordance with regulations and
protocols sanctioned by the Human Subjects Committee
of Helsinki and were approved by the Sapienza Institu-
tional Review Board (protocol number 158/10 signed on
February 18, 2010). MNC obtained from the PB of a nor-
mal volunteer donor and blast cells from the BM of AML
patients were separated by layering on Ficoll-Hypaque
density gradient (Lymphoprep; 1.007 g/mL). Cells used
for in vitro studies were resuspended at a concentration
of 1.0× 106/mL, in RPMI 10% FCS±TR at scalar concentra-
tions (0.5–2mg/mL). In particular, the circulating mononu-
clear cells obtained from healthy donors were placed in
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liquid culture± scalar concentrations of TR in the absence
and in the presence of a proliferative stimulus (PHA).
2.5. Cell Cycle and Apoptosis Analysis. Cell cycle distribution
changes were evaluated using the Acridine Orange (AO)
technique as previously described [23]. The percentage of
cells in G0, G1, S, and G2M was determined by measuring
simultaneously the DNA and RNA total cellular content.
The percentage of apoptotic cells was measured based on
the decreased stainability of apoptotic elements in DNA
green ﬂuorescence (sub-G0/1 peak on DNA frequency
histograms) coupled with a higher RNA red ﬂuorescence
(which is common to chromatin condensation); cell debris
was excluded from the analysis on the basis of their forward
light scatter properties. Cell cycle distribution was analyzed
using the ModFit LT software (Verity Software House,
Topsham, ME).
Induction of apoptosis was also assessed by measuring
Annexin V binding to externalized phosphatidylserine, as
previously described [24]. Brieﬂy, cells were washed twice
with PBS and resuspended in binding buﬀer (10mM
Hepes/NaOH pH7.4, 140mM NaCl, 2.5mM CaCl2,
Sigma Chemical Co.). FITC-conjugated Annexin V (Roche
Diagnostic Corp., Indianapolis, Indiana, USA) was added
at a ﬁnal concentration of 1μg/mL. The mixture was
incubated at room temperature for 15min in the dark
prior to ﬂow cytometric analysis. Membrane integrity
was simultaneously assessed by propidium iodide (PI,
0.25μg/mL) exclusion.
2.6. Analysis of Intracellular ROS Levels. The generation of
ROS was measured by using DCFH-DA, a ROS-sensitive
ﬂuorescent probe. Brieﬂy, OCI-AML3 cells were cultured
for 24h with diﬀerent concentrations of TR. After exposure,
cells were incubated with 10mM DCFH-DA for 30min at
37°C, then washed, resuspended in PBS, and immediately
analyzed by ﬂow cytometry. Results were expressed as mean
ﬂuorescence intensity (MFI) relative to that of control.
2.7. Statistical Analysis. The two-sided Student t-test was
used to evaluate the signiﬁcance of diﬀerences between
groups. Results were expressed as the mean± standard
deviation (SD). Values of p < 0 05 were considered signiﬁ-
cant from a statistical point of view.
3. Results
3.1. Eﬀects of TR on Leukemia Cell Lines. We started to
evaluate the eﬀects of TR on human myeloid (OCI-AML3)
and lymphoid (Jurkat) leukemia cell lines exposed to scalar
concentrations of TR (0.5–2mg/mL). Cell aliquots were
harvested at 24, 48, and 72 hours and analyzed for cell
counts (trypan blue), cell cycle (ﬂow cytometric analysis
by AO), and apoptosis (ﬂow cytometry assessment with
AO, Annexin V).
Exposure to TR induced a dose- and time-dependent
reduction in cell count in all hematopoietic cell lines studied
(Figure 1). In fact, the eﬀects were markedly evident at a dose
of 1mg/mL after 48 hours of liquid culture. The prolonged
exposure to TR and increasing scalar concentrations of the
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Figure 1: TR induces a dose-dependent reduction in cell count in hematopoietic cell lines. Jurkat and OCI-AML3 cells were exposed to
increasing concentrations of TR for the indicated time points. Cell counts and viability were then assessed by trypan blue exclusion
counting. Results are expressed as the average± SD of seven independent experiments.
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molecule potentiated the eﬀectiveness (Figure 1). Detection
of cell cycle changes, measured at the same time points,
however, showed that on leukemia cell lines TR was unable
to aﬀect cell cycle distribution and apoptosis. Only on Jurkat
cell line it was observed, after 72 h of culture, a mild, not
signiﬁcant, dose-dependent increase of cells in G0 phase
associated with a decrease of G1 and S compartment and
with a nonsigniﬁcant increase of sub-G0/1 (Figure 2).
Analysis of intracellular ROS levels in cells stained with
DCFH-DA depicts (Figure 3) that TR induced accumulation
of ROS as demonstrated by an increase of DCFH-DA MFI in
OCI-AML3 treated with TR as compared to control: from
MFI of 0.46× 106 (control) to MFI of 2.94× 106, 2.61× 106
and, 2.98× 106 in the presence of 0.5, 1, and 2mg/mL
TR, respectively.
3.2. Eﬀects of TR on Primary Cells from AML Patients. We
then examined the biological eﬀects induced in vitro by TR
on primary cells from 4 patients with newly diagnosed
AML. Our results indicate that TR induced reduction in
cell count and signiﬁcant cytotoxic eﬀects in a dose- and
time-dependent fashion in all (4/4) samples studied. After
72–120 hours of culture, TR was able to exert a signiﬁcant
reduction in cell counts from 1272500± 235425 cells/mL,
in the control condition, to 885000± 392386 (p = 0 06),
787500± 493381 (p = 0 04), 675000± 470213 (p = 0 02), and
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Figure 2: TR induces a dose-dependent increase of cells in G0 phase of cell cycle in hematopoietic cell lines. Jurkat cells were exposed to
increasing concentrations of TR. Cell cycle changes were then evaluated by the AO technique. Results showed are representative of
7 independent experiments (a). Percentages of cells in G0 phase after 72 h of TR exposure are shown in (b).
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391750± 356435 (p = 0 01) cells/mL in the presence of 0.5,
0.8, 1, and 2mg/mL of TR, respectively (Figure 4).
Notably, in primary AML samples, TR signiﬁcantly
increased apoptosis levels (sub-G0/1) from 35.7± 13.8%,
in the control conditions, to 48.9%± 23.5, 67.9%± 25.9,
65.9%± 34.6, and 77.2%± 28.3 (p = 0 04) in the presence of
0.5, 0.8, 1, and 2mg/mL of TR, respectively (Figure 5(a)).
This eﬀect was, however, even more marked at a prolonged
exposure to the molecule (144–168 hours), reaching the
statistical signiﬁcance already at the lowest dose: from
41.6%± 23.5, in the control condition, to 77.5%± 31.1 (p =
0 04), 88.6%± 17.3 (p = 0 01), 86.5%± 22.8 (p = 0 01), and
94.5%± 8.4 (p = 0 01), with 0.5, 0.8, 1, and 2mg/mL of TR,
respectively (Figures 5(b) and 5(c)).
3.3. Eﬀects of TR on Normal Cells. In order to analyze the
activity of the compound on normal hematopoietic cells, we
investigated the eﬀects of TR on mononuclear cells obtained
from PB of normal donors. The MNC were then exposed in
liquid culture±TR at scalar concentrations (0.5, 0.8, 1, and
2mg/mL), in the absence and in the presence of a prolifera-
tive stimulus (PHA). The results obtained showed that TR
was able to induce only a moderate, not statistically signiﬁ-
cant, proapoptotic activity, regardless of the dose: after 72
hours, apoptosis levels were 18.3%± 15.6, in the control con-
dition, and 25.65%± 10.0, 29.5%± 18.4, 35.5%± 16.2, and
31.8%± 15.8, with 0.5, 0.8, 1, and 2mg/mL of TR, respec-
tively (Figure 6(a)). These eﬀects were not enhanced by
the pretreatment with PHA: at 48 hours, apoptosis levels
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Figure 3: TR induced accumulation of ROS in hematopoietic cells line. Cells were exposed to increasing concentrations of TR. After 24 h, cells
were stained with DCFH-DA for intracellular ROS level analysis.
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Figure 4: TR induces a dose- and time-dependent reduction in cell count in primary cells from AML patients. AML primary cells were
exposed to the indicated concentrations of TR. Cell counts and viability were assessed for the individual sample after 72–120 h and
144–168 h by trypan blue exclusion.
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were 20.1%± 5.0, in the control condition, and 18.9%± 5.6,
14.1%± 2.6, 23.4%± 14.9, and 13.3%± 1.0, with 0.5, 0.8, 1,
and 2mg/mL of TR, respectively (Figure 6(b)).
4. Discussion
The present study demonstrated that TR, a polysaccharide
extract from T. versicolor, signiﬁcantly suppresses cell
growth of human leukemia cell lines from diﬀerent onto-
genesis and exerts a cytotoxic activity on primary cells from
AML patients.
T. versicolor is one of the most commonly used
medicinal mushrooms, and several extracts have already
been investigated for their antineoplastic eﬀects. The cyto-
toxic activity of PSP and PSK extract from T. versicolor has
been reported in myeloid and lymphoid leukemia cell line
[25, 26]. It was also demonstrated that an ethanol-water
extract from wild T. versicolor exerted in vitro antiprolifer-
ative and cytotoxic eﬀects against leukemia and lymphoma
cell lines [26]. Moreover, the antioxidant eﬀects of diﬀer-
ent molecular mass enzymatic hydrolysates from PSPs
were described [27]. In addition, results from a phase 1
clinical trial proved that an orally administered prepara-
tion from the T. versicolor may improve immune response
in women with breast cancer after standard chemotherapy
and radiotherapy [14].
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Figure 5: TR induces a dose- and time-dependent apoptosis in primary cells from AML. AML primary cells were exposed to the
indicated concentrations of TR. Apoptosis induction was then evaluated by the AO technique. Percentages of sub-G0/1 cells are
shown for the individual sample after 72–120 h (a) and 144–168 h (b) exposure to scalar concentrations of TR. A representative
experiment is shown (c).
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We demonstrated, for the ﬁrst time at our knowledge, the
in vitro cytotoxic activity of a polysaccharidic fraction
puriﬁed from T. versicolor on primary AML cells, as shown
by a time- and dose-dependent induction of apoptosis.
One of the fundamental hallmarks of cancer cells is
their capacity to proliferate persistently, eluding cell cycle
checkpoint controls and growth inhibitory signals [28, 29].
Moreover, the acquired resistance toward apoptosis repre-
sents another key hallmark of cancer. Hence, molecules
capable to block the uncontrolled proliferation and/or to
induce to cell death have been evermore considered very
promising for therapeutic applications in cancers. Previous
reports demonstrated that PSK induces in vitro cytotoxic
activity in tumor cell lines, via arrest of cell cycle and
induction of apoptosis [11, 15].
Data presented in our study demonstrated that TR causes
in leukemia models a dose-dependent increase of cells in G0
phase and a decrease in both G1 and S phases. Nevertheless,
lack of statistical signiﬁcance argues in favor of a deceleration
of cell cycle rather than a cell cycle arrest and apoptosis
induction at these concentrations. The preclinical relevance
of TR was showed on primary samples obtained from de
novo AML patients. TR was indeed able to decrease the
leukemic blast viability by signiﬁcantly inducing apoptosis
in all AML samples tested. By contrast, no signiﬁcant
cytotoxicity was observed on resting and activated normal
MNC thus suggesting the existence of a therapeutic window
in leukemia setting.
The direct antiproliferative eﬀect of several fungal poly-
saccharides on cancer cells, caused by cell cycle arrest and
apoptosis induction, has been also reported associated with
oxidative stress [30, 31]. Here, in fact, we documented ROS
accumulation in leukemia cell line. It was widely described
that oxidants can contribute to cancer development by
promoting cell mutation and growth [32]. Nevertheless,
it was also reported that excessive oxidative stress can
slow proliferation and induce cell death [32]. TR-induced
cytotoxicity observed in primary AML samples could then
be due to oxidative stress-induced cell death.
Although the literature seems to suggest the involvement
of Toll-like receptors or of other cell surface receptors in the
increased oxidative stress induced by fungal polysaccharides
[33, 34], the exact mechanism remains to be clariﬁed.
In conclusion, the cytotoxic preclinical activity of TR
on primary leukemia cells, as compared to normal MNC
obtained from healthy cells, makes TR an interesting
bioactive compound among other antileukemic treatments
and prompts further investigation aiming to elucidate its
mechanism of action for a translational application.
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